Drug Profile
Research programme: microbiome therapeutics - Memorial Sloan Kettering Cancer Center/Seres Therapeutics
Latest Information Update: 15 Jun 2023
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Memorial Sloan-Kettering Cancer Center; Seres Therapeutics
- Class Antineoplastics; Bacteria
- Mechanism of Action Bacteria replacements; Immunomodulators; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
- Discontinued Graft-versus-host disease
Most Recent Events
- 15 Jun 2023 Preclinical research in Cancer is ongoing in USA (Seres Therapeutics pipeline, June 2023)
- 15 Jun 2023 Discontinued - Preclinical for Graft-versus-host disease (Prevention) in USA (unspecified route)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Cancer in USA